Alvotech (NASDAQ:ALVO) Stock Lifted to “Hold” by Wall Street Zen

Wall Street Zen upgraded shares of Alvotech (NASDAQ:ALVO – Free Report) from a sell rating to a hold rating in a report issued on Sunday,Wall Street Zen reports.

A number of other research firms have also recently issued reports on ALVO. Evercore began coverage on shares of Alvotech in a research note on Friday, August 14th. They set an “outperform” rating for the company. Zacks Research downgraded Alvotech from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 20th. Weiss Ratings upgraded Alvotech from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, November 4th. Barclays raised shares of Alvotech from an “underweight” rating to an “overweight” rating and boosted their target price for the company from $4.00 to $8.00 in a research report on Wednesday, September 16th. Finally, Bank of America assumed coverage on Alvotech in a research report on Monday, August 24th. They issued a “buy” rating and a $7.00 price target on the stock. Five investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $8.40.

Read Our Latest Stock Analysis on Alvotech

Alvotech Price Performance

Shares of NASDAQ ALVO opened at $4.19 on Friday. The business’s 50 day moving average price is $5.23 and its two-hundred day moving average price is $4.20. The company has a market cap of $1.26 billion, a PE ratio of -5.11 and a beta of 0.24. Alvotech has a twelve month low of $2.94 and a twelve month high of $6.53.

Alvotech (NASDAQ:ALVO – Get Free Report) last released its quarterly earnings data on Wednesday, November 11th. The company reported ($0.03) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.03). The business had revenue of $111.60 million during the quarter, compared to analyst estimates of $123.45 million. As a group, research analysts anticipate that Alvotech will post -0.01 EPS for the current fiscal year.

Hedge Funds Weigh In On Alvotech

A number of hedge funds have recently modified their holdings of ALVO. Ulland Investment Advisors LLC increased its stake in shares of Alvotech by 5.0% in the 3rd quarter. Ulland Investment Advisors LLC now owns 115,000 shares of the company’s stock worth $667,000 after acquiring an additional 5,500 shares in the last quarter. ProShare Advisors LLC bought a new stake in Alvotech during the third quarter worth about $68,000. Commonwealth Equity Services LLC bought a new stake in Alvotech during the third quarter worth about $69,000. China Universal Asset Management Co. Ltd. boosted its stake in Alvotech by 24.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 61,712 shares of the company’s stock worth $365,000 after acquiring an additional 12,049 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in Alvotech in the third quarter worth about $100,000.

Recent Alvotech Headlines

Investors following ALVO have been watching these headlines:

  • Positive Sentiment: Alvotech forecast 2026 revenue of $650 million–$700 million, broadly around or above the $652.5 million consensus at the midpoint, and EBITDA of $180 million–$220 million. Management said it expects the fourth quarter to be the strongest in company history. Article: Alvotech targets $650M-$700M revenue and $180M-$220M EBITDA
  • Neutral Sentiment: The earnings call highlighted growth opportunities alongside business risks; the available article summary did not specify further details. Article: Alvotech Earnings Call Highlights Growth and Risks
  • Negative Sentiment: Q3 revenue of $111.6 million fell short of the $125.2 million analyst estimate. Alvotech posted a loss of $0.03 per share; while that beat one reported consensus estimate of a $0.04 loss, it missed Zacks’ estimate of a $0.01 loss. The revenue miss and mixed earnings comparisons could pressure the shares. Article: Alvotech Reports Q3 Loss, Lags Revenue Estimates

About Alvotech

(Get Free Report)

Alvotech is a biopharmaceutical company based in Reykjavik, Iceland, focused on developing and manufacturing biosimilars—medicines designed to be highly similar to existing biologic drugs. Its work includes biosimilars for conditions in areas such as immunology and oncology. Founded in 2013 by entrepreneur Robert Wessman, the company operates an integrated development and manufacturing platform in Iceland. Alvotech works with commercial partners to seek regulatory approval for and distribute its products in markets including the United States and Europe.

See Also

Analyst Recommendations for Alvotech (NASDAQ:ALVO)

Receive News & Ratings for Alvotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alvotech and related companies with MarketBeat.com's FREE daily email newsletter.